Nicolas Deconinck

Nicolas Deconinck

Auto-generated profile, based on publicly available information

Nicolas Deconinck

Department of Paediatric Neurology, Hôpital Universitaire des Enfants Reine Fabiola, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2023 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
MOMaryam Oskoui
Maryam Oskoui
JDJohn W. Day
John W. Day
NDNicolas Deconinck
Nicolas Deconinck
EMELENA MAZZONE
ELENA MAZZONE
ANAndres Nascimento
Andres Nascimento
OGon behalf of The SUNFISH Working Group
on behalf of The SUNFISH Working Group
Risdiplam is an oral, survival of motor neuron 2 (SMN2) pre-mRNA splicing modifier approved for the treatment of spinal muscular atrophy (SMA). SUNFISH (NCT02908685) Part 2, a Phase 3, randomized, double-blind, placebo-controlled study, investigated the efficacy and safety of risdiplam in type 2 and non‑ambulant type 3 SMA. The primary endpoint was met: a significantly greater change from baseline in 32-item Motor Function Measure (MFM32) total score was observed with risdiplam compared with placebo at month 12. After 12 months, all participants received risdiplam while preserving initial treatment blinding. We report 24-month efficacy and safety results in this population. Month 24 exploratory endpoints included change from baseline in MFM32 and safety. MFM‑derived results were compared with an external comparator. At month 24 of risdiplam treatment, 32% of patients demonstrated improvement (a change of ≥ 3) from baseline in MFM32 total score; 58% showed stabilization (a change of ≥ 0). Compared with an external comparator, a treatment difference of 3.12 (95% confidence interval [CI] 1.67–4.57) in favor of risdiplam was observed in MFM-derived scores. Overall, gains in motor function at month 12 were maintained or improved upon at month 24. In patients initially receiving placebo, MFM32 remained stable compared with baseline (0.31 [95% CI – 0.65 to 1.28]) after 12 months of risdiplam; 16% of patients improved their score and 59% exhibited stabilization. The safety profile after 24 months was consistent with that observed after 12 months. Risdiplam over 24 months resulted in further improvement or stabilization in motor function, confirming the benefit of longer-term treatment.

18 April 2023 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
MOMaryam Oskoui
Maryam Oskoui
JDJohn W. Day
John W. Day
NDNicolas Deconinck
Nicolas Deconinck
EMELENA MAZZONE
ELENA MAZZONE
ANAndres Nascimento
Andres Nascimento
OGon behalf of The SUNFISH Working Group
on behalf of The SUNFISH Working Group
The original version of this article unfortunately contained a mistake. The corrected details are given below for your reading. In figure 1, there is an error in the n numbers below the graph in Panel 1b for the placebo group. The n numbers underneath Panel 1b should be 58 58 50.

6 April 2024 in Movement Disorders
Verified
Journal Article
Open access
RKRauan Kaiyrzhanov
Rauan Kaiyrzhanov
JOJuan Darío Ortigoza‐Escobar
Juan Darío Ortigoza‐Escobar
BSBrett Stringer
Brett Stringer
MGManizha Ganieva
Manizha Ganieva
VGVykuntaraju K Gowda
Vykuntaraju K Gowda
RMReza Maroofian
Reza Maroofian
Background: Based on a limited number of reported families, biallelic CA8 variants have currently been associated with a recessive neurological disorder named, cerebellar ataxia, mental retardation, and dysequilibrium syndrome 3 (CAMRQ‐3).Objectives: We aim to comprehensively investigate CA8‐related disorders (CA8‐RD) by reviewing existing literature and exploring neurological, neuroradiological, and molecular observations in a cohort of newly identified patients.Methods: We analyzed the phenotype of 27 affected individuals from 14 families with biallelic CA8 variants (including data from 15 newly identified patients from eight families), ages 4 to 35 years. Clinical, genetic, and radiological assessments were performed, and zebrafish models with ca8 knockout were used for functional analysis.Results: Patients exhibited varying degrees of neurodevelopmental disorders (NDD), along with predominantly progressive cerebellar ataxia and pyramidal signs and variable bradykinesia, dystonia, and sensory impairment. Quadrupedal gait was present in only 10 of 27 patients. Progressive selective cerebellar atrophy, predominantly affecting the superior vermis, was a key diagnostic finding in all patients. Seven novel homozygous CA8 variants were identified. Zebrafish models demonstrated impaired early neurodevelopment and motor behavior on ca8 knockout.Conclusion: Our comprehensive analysis of phenotypic features indicates that CA8‐RD exhibits a wide range of clinical manifestations, setting it apart from other subtypes within the category of CAMRQ. CA8‐RD is characterized by cerebellar atrophy and should be recognized as part of the autosomal‐recessive cerebellar ataxias associated with NDD. Notably, the presence of progressive superior vermis atrophy serves as a valuable diagnostic indicator. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

24 January 2025 in Annals of Neurology
Verified
Journal Article
Open access
SCSandra Coppens
Sandra Coppens
NDNicolas Deconinck
Nicolas Deconinck
PSPatricia Sullivan
Patricia Sullivan
ASAndrei Smolnikov
Andrei Smolnikov
JCJoshua Clayton
Joshua Clayton
EOEmily C. Oates
Emily C. Oates
Congenital titinopathy has recently emerged as one of the most common congenital muscle disorders.Objective: To better understand the presentation and clinical needs of the under‐characterized extreme end of the congenital titinopathy severity spectrum.Methods: We comprehensively analyzed the clinical, imaging, pathology, autopsy, and genetic findings in 15 severely affected individuals from 11 families.Results: Prenatal features included hypokinesia or akinesia and growth restriction. Six pregnancies were terminated. Nine infants were born at or near term with severe‐to‐profound weakness and required resuscitation. Seven died following withdrawal of life support. Two surviving children require ongoing respiratory support. Most cohort members had at least 1 disease‐causing variant predicted to result in some near‐normal‐length titin expression. The exceptions, from 2 unrelated families, had homozygous truncating variants predicted to induce complete nonsense mediated decay. However, subsequent analyses suggested that the causative variant in each family had an additional previously unrecognized impact on splicing likely to result in some near‐normal‐length titin expression. This impact was confirmed by minigene assay for 1 variant.Interpretation: This study confirms the clinical variability of congenital titinopathy. Severely affected individuals succumb prenatally/during infancy, whereas others survive into adulthood. It is likely that this variability is because of differences in the amount and/or length of expressed titin. If confirmed, analysis of titin expression could facilitate clinical prediction and increasing expression might be an effective treatment strategy. Our findings also further‐support the hypothesis that some near‐normal‐length titin expression is essential to early prenatal survival. Sometimes expression of normal/near‐normal‐length titin is due to disease‐causing variants having an additional impact on splicing. ANN NEUROL 2025;97:611–628

1 February 2009 in Current Pediatric Reviews
Verified
Journal Article
Closed access
PDF file
NDNicolas Deconinck
Nicolas Deconinck
TSTanya Stojkovic
Tanya Stojkovic
Abstract: Ullrich congenital muscular dystrophy (UCMD) is a genetically and clinically heterogeneous muscle disorder causing severe muscle weakness with proximal joint contractures and distal hyperlaxity linked to collagen VI deficiency. It was initially described within the wider group of muscular congenital dystrophies. Collagen VI is an extracellular matrix protein forming a microfibrillar network. The protein is composed of three different α-chains encoded by separate genes named COL6A1, COL6A2, and COL6A3 in humans. Mutations of collagen VI gene are also responsible for Bethlem myopathy (BM), a relatively mild dominantly inherited disorder characterised by proximal weakness and distal joint contractures that was previously believed to be a completely separate entity. The pathogenesis of both diseases is still poorly understood. However, some recent data, obtained from experiments mouse models and from human myoblast cultures provide valuable insights into the pathogenesis of UCMD. A potential mitochondrial involvement may become the focus of specific therapeutic approaches. In this review we emphasise the typical clinical and biochemical findings that will help the paediatrician to identify collagenopathies within the complex diagnostic group of congenital muscular dystrophies, and outline the current understanding of UCMD pathogenesis, management, and potential therapeutic avenues.

1 December 2011
Verified
Journal Article
Closed access
MKMouna Al Husni Al Keilani
Mouna Al Husni Al Keilani
SCSophie Carlier
Sophie Carlier
JGJosé Groswasser
José Groswasser
BDBernard Dan
Bernard Dan
NDNicolas Deconinck
Nicolas Deconinck